- Home
- PMTS vs PRQR Comparison
PMTS vs PRQR Comparison
Compare PMTS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- PRQR
- Stock Information
- Founded
- PMTS 2007
- PRQR 2012
- Country
- PMTS United States
- PRQR Netherlands
- Employees
- PMTS N/A
- PRQR N/A
- Industry
- PMTS Finance Companies
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- PRQR Health Care
- Exchange
- PMTS Nasdaq
- PRQR Nasdaq
- Market Cap
- PMTS 172.6M
- PRQR 232.8M
- IPO Year
- PMTS 2015
- PRQR 2014
- Fundamental
- Price
- PMTS $14.89
- PRQR $2.19
- Analyst Decision
- PMTS Strong Buy
- PRQR Strong Buy
- Analyst Count
- PMTS 4
- PRQR 8
- Target Price
- PMTS $34.00
- PRQR $8.88
- AVG Volume (30 Days)
- PMTS 40.1K
- PRQR 370.2K
- Earning Date
- PMTS 11-04-2025
- PRQR 11-06-2025
- Dividend Yield
- PMTS N/A
- PRQR N/A
- EPS Growth
- PMTS N/A
- PRQR N/A
- EPS
- PMTS 1.11
- PRQR N/A
- Revenue
- PMTS $502,361,000.00
- PRQR $20,129,184.00
- Revenue This Year
- PMTS $14.84
- PRQR N/A
- Revenue Next Year
- PMTS $10.55
- PRQR N/A
- P/E Ratio
- PMTS $13.40
- PRQR N/A
- Revenue Growth
- PMTS 14.31
- PRQR 8.65
- 52 Week Low
- PMTS $12.52
- PRQR $1.07
- 52 Week High
- PMTS $35.19
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PMTS 41.96
- PRQR 47.76
- Support Level
- PMTS $13.82
- PRQR $2.21
- Resistance Level
- PMTS $16.31
- PRQR $2.50
- Average True Range (ATR)
- PMTS 0.75
- PRQR 0.14
- MACD
- PMTS 0.19
- PRQR -0.01
- Stochastic Oscillator
- PMTS 42.14
- PRQR 32.61
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.